Since IL-10 is a potent anti-inflammatory cytokine, and several in vivo studies have shown its protective role in a variety of pathological states (e.g. colitis, hepatic ischemia/reperfusion and myocardial ischemia/reperfusion), a reduced production due to bIAP treatment would not be favorable [27-29]. This evidence concerns the gene IL10 and colitis.